Uncategorized

The SOLIDARITY Data

  • by

OK, we have some more to think about this morning. The large SOLIDARITY trial from the WHO has reported more interim data on its investigation into repurposed drugs for the coronavirus pandemic. And some of this we already knew, but some of it’s a real… Read More »The SOLIDARITY Data

Immunity and Re-Infection

  • by

For months now, people have been watching closely to see if it’s possible to get re-infected with the coronavirus. It’s taken a while for the signal-to-noise to get better, but by now there’s no doubt that the answer is yes, it’s possible. We’ve just had… Read More »Immunity and Re-Infection

Another Vaccine Trial Halt

  • by

The first advice is “Don’t panic”. You will have heard that last night J&J announced that their coronavirus vaccine dosing has been paused while they investigate an adverse event in the trial. And while you never like to hear that, considering the size of their… Read More »Another Vaccine Trial Halt

Cigna’s Evernorth Expands Digital Health Formulary with Addition of Omada MSK by Physera

  • by

What You Should Know: – Cigna Corporation’s health services segment, Evernorth expands its digital health formulary with the addition of Omada MSK by Physera. – Omada MSK by Physera joins Omada’s existing formulary programs for diabetes prevention, type 2 diabetes, and hypertension. Cigna Corporation’s health… Read More »Cigna’s Evernorth Expands Digital Health Formulary with Addition of Omada MSK by Physera

A Nobel for CRISPR

  • by

The 2020 Chemistry Nobel has gone to Jennifer Doudna and Emmanuelle Charpentier for the discovery of CRISPR. An award in this area has been expected for some time – it’s obviously worthy – so the main thing people have been waiting for is to see… Read More »A Nobel for CRISPR

2020 Cold Chain Provider Directory

  • by

Download the 2020 Cold Chain Vendor and Service Provider Directory here. The post 2020 Cold Chain Provider Directory appeared first on Pharmaceutical Commerce.

Should more flexible health care professional licensing continue after COVID-19?

  • by

Shirley Svorny and Michael Cannon of the Cato Institute have a long history (see here) of criticizing government licensing of physicians and other health care providers (e.g., nurse practitioners [NPs], nurses). Their proposed alternative has been to allow private entities to certify the competence of… Read More »Should more flexible health care professional licensing continue after COVID-19?

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

  • by

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company,… Read More »BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

  • by

Shots: The EC has granted MAA to Kaftrio (ivacaftor/tezacaftor/lumacaftor) + ivacaftor (150mg) to treat people with CF aged ≥12yrs. with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the CFTR gene The MAA is based on two P-III… Read More »Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

  • by

Shots: The US FDA has approved Janssen’s Darzalex + Amgen’s Kyprolis (carfilzomib) and dexamethasone (DKd)  in two dosing regimen (70 mg/m2 , qw and 56 mg/m2 , q2w) for the treatment of adult patients with r/r MM who have received 1-3L therapies The approval of… Read More »The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

Drug Repurposing: An Overview 

  • by

This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 194-212 under an… The post Drug Repurposing: An Overview  appeared first on DrugPatentWatch – Make Better Decisions.

Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19

  • by

Shots: The two global companies collaborated to develop, manufacture, and distribute REGN-COV2 across the globe. The agreement is expected to increase the supply of REGN-COV2 to at least 3.5 times the current capacity with the potential for expanding it further Regeneron will lead the distribution… Read More »Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19

Links

  • by

Kamala Harris on health. COVID data quality. African-American views on US health policy. Impact of treatment advances on lung cancer mortality. Trends in deaths of despair.

Pharma Whatsapp Group

  • by

Pharma Whatsapp Group Whatsapp When Join Pharma Pathway Group You get 250+ vacancies direct Your Phone Group Rules – Welcome to Everyone Pharma Pathway Some Rules To Be Followed In This Group: 1. People will be removed from the group without any intimation, if u… Read More »Pharma Whatsapp Group

That Kodak Deal

  • by

Many people have been wondering what’s going on with the announcement by the Trump administration that Kodak has been contracted to produce pharmaceutical APIs here in the US. Let’s line up some of the public statements about all this first, and then take a closer… Read More »That Kodak Deal

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease

  • by

Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of… Read More »Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease

Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020

  • by

Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020 Umedica Laboratories -Walk-In Interviews for Freshers & Experienced -Manufacturing / Packing / Injection / QA Departments Time & Venue Details : Walk-In On 27th to 29th July’ 2020 At Umedica Laboratories,… Read More »Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020

WordPress Resources at SiteGround

  • by

WordPress is an award-winning web software, used by millions of webmasters worldwide for building their website or blog. SiteGround is proud to host this particular WordPress installation and provide users with multiple resources to facilitate the management of their WP websites: Expert WordPress Hosting SiteGround… Read More »WordPress Resources at SiteGround

Actiza Pharmaceutical Pvt Ltd. is a strong presence in Injectable manufacturing

Actiza Pharmaceutical Pvt Ltd. is a rapidly growing Indian pharmaceutical company with a strong presence in Injectable manufacturing. Established in 2011, Actiza Pharmaceutical has emerged as one of the largest focused small volume parenteral manufacturer in India and is engaged in contract manufacturing for all… Read More »Actiza Pharmaceutical Pvt Ltd. is a strong presence in Injectable manufacturing